Combination of bleomycin, etoposide and cisplatin (BEP) versus etoposide and cisplatin (EP) in patients with good risk nonseminomatous germ cell tumors (NSGCT)

被引：0

作者：

Tryakin, A. ^{[1
]}

Fedyanin, M. ^{[1
]}

Bulanov, A. ^{[1
]}

Titov, D. ^{[1
]}

Mitin, A. ^{[2
]}

Sergeev, J. ^{[3
]}

Figurin, K. ^{[2
]}

Fainstein, I. ^{[3
]}

Matveev, V. ^{[2
]}

Zakharova, T. ^{[4
]}

Kostjakova, L. ^{[5
]}

Garin, A. ^{[1
]}

Tjulandin, S. ^{[1
]}

机构：

[1] NN Blokhin Russian Canc Res Ctr, Clin Pharmacol & Chemotherapy, Moscow, Russia

[2] NN Blokhin Russian Canc Res Ctr, Urol, Moscow, Russia

[3] NN Blokhin Russian Canc Res Ctr, Radiosurg, Moscow, Russia

[4] NN Blokhin Russian Canc Res Ctr, Pathomorphol, Moscow, Russia

[5] NN Blokhin Russian Canc Res Ctr, Radiol, Moscow, Russia

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)31428-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2610

引用

页码：S515 / S515

页数：1

共 50 条

[41] TREATMENT OF POOR RISK NONSEMINOMATOUS GERM-CELL TUMOR (NSGCT) PATIENTS (PTS) WITH CARBOPLATIN(CBDCA)+ETOPOSIDE(E) + BLEOMYCIN (B) [J].

MOTZER, RJ ;

BOSL, GJ ;

YAGODA, A ;

GOLBEY, R .

PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 :202-202

[42] Neurologic late toxicity in testicular cancer patients treated with bleomycin, etoposide and cisplatin (bep) combination chemotherapy. [J].

Bavbek, SE ;

Basaran, M ;

Saip, S ;

Eralp, Y ;

Sakar, B ;

Onat, H .

ANNALS OF ONCOLOGY, 2000, 11 :78-78

[43] Prognostic factors and survival in germ cell cancer (GCC) patients treated with bleomycin, etoposide, and cisplatin (BEP): A population-based study [J].

Kier, M. G. G. ;

Lauritsen, J. ;

Mortensen, M. S. ;

Bandak, M. ;

Andersen, K. K. ;

Hansen, M. K. ;

Agerbaek, M. ;

Holm, N. V. ;

Dalton, S. O. ;

Johansen, C. ;

Daugaard, G. .

ANNALS OF ONCOLOGY, 2016, 27

[44] Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT). [J].

Feldman, Darren R. ;

Hu, James S. ;

Patil, Sujata ;

Reuter, Victor E. ;

Srinivas, Sandy ;

Stadler, Walter Michael ;

Costello, Brian Addis ;

Milowsky, Matthew I. ;

Appleman, Leonard Joseph ;

Dorff, Tanya B. ;

Bromberg, Maria ;

Joseph, Gabriella ;

Funt, Samuel Aaron ;

Bajorin, Dean F. ;

Bosl, George J. ;

Quinn, David I. ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[45] TREATMENT OF POOR-RISK GERM-CELL TUMORS WITH HIGH-DOSE CISPLATIN AND ETOPOSIDE COMBINED WITH BLEOMYCIN [J].

DAUGAARD, G ;

RORTH, M .

ANNALS OF ONCOLOGY, 1992, 3 (04) :277-282

[46] Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). [J].

Feldman, Darren R. ;

Hu, James ;

Srinivas, Sandy ;

Stadler, Walter Michael ;

Costello, Brian Addis ;

Appleman, Leonard Joseph ;

Milowsky, Matthew I. ;

Patil, Sujata ;

Bromberg, Maria ;

Nolan, Patrick ;

Dorff, Tanya B. ;

Reuter, Victor E. ;

Al-Ahmadie, Hikmat ;

Funt, Samuel ;

Bajorin, Dean F. ;

Bosl, George J. ;

Quinn, David I. ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[47] Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group [J].

Bamias, Aristotelis ;

Aravantinos, Gerassimos ;

Kastriotis, Ioannis ;

Alivizatos, Gerassimos ;

Anastasiou, Ioannis ;

Christodoulou, Christos ;

Gyftaki, Reveka ;

Kalofonos, Haralambos P. ;

Dimopoulos, Meletios A. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) :189-193

[48] THE OPTIMIZATION OF CARBOPLATIN DOSE IN CARBOPLATIN, ETOPOSIDE AND BLEOMYCIN COMBINATION CHEMOTHERAPY FOR GOOD PROGNOSIS METASTATIC NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS [J].

CHILDS, WJ ;

NICHOLLS, EJ ;

HORWICH, A .

ANNALS OF ONCOLOGY, 1992, 3 (04) :291-296

[49] A randomized trial of 72-hour infusional bleomycin in BEP (cisplatin, etoposide, and bleomycin) versus conventional weekly bleomycin in patients with metastatic IGCCCG good prognosis disease [J].

Vinnicombe, Sarah ;

Harland, Stephen John ;

Joffe, Johnathan K. ;

Huddart, Robert ;

Mazhar, Danish ;

Birtle, Alison J. ;

White, Jeff D. ;

Wilson, Peter ;

Marshall, Marita ;

Sarker, Shah-Jalal ;

Shamash, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[50] Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin [J].

Xiao, H ;

Mazumdar, M ;

Bajorin, DF ;

Sarosdy, M ;

Vlamis, V ;

Spicer, J ;

Ferrara, J ;

Bosl, GJ ;

Motzer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2553-2558

← 1 2 3 4 5 →